Phase i trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in syn3 for bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer

Journal of Urology

Volumn 190, Issue 3, 2013, Pages 850-856

  Dinney, Colin P N ^a   Fisher, Mark B ^a   Navai, Neema ^a   O'Donnell, Michael A ^b   Cutler, David ^c,d,e   Abraham, Alice ^a   Young, Sophia ^c,d,e   Hutchins, Beth ^c,d,e   Caceres, Maria ^c,d,e   Kishnani, Narendra ^c,d,e   Sode, George ^c,d,e   Cullen, Constance ^c,d,e   Zhang, Guangcheng ^a   Grossman, H Barton ^a   Kamat, Ashish M ^a   Gonzales, Marshall ^a   Kincaid, Michael ^a   Ainslie, Nancy ^a   Maneval, Daniel C ^f   Wszolek, Matthew F ^a   Benedict, William F ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Union and Kenilworth   (United States)

^e Palo Alto CA ^*  (United States)

^f Halozyme Therapeutics Inc   (United States)

Author keywords

genetic therapy; interferons; urinary bladder neoplasms

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; BCG VACCINE; DNA; EXCIPIENT; RECOMBINANT ADENOVIRUS MEDIATED INTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ADENOVIRUS; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION;

ADVERSE EVENT; AE; ALIVE WITH DISEASE; AWD; BACILLUS CALMETTE-GUÉRIN; BCG; COMPLETE RESPONSE; CR; DLT; DOSE LIMITING TOXICITY; GENETIC THERAPY; IFN; INTERFERON; INTERFERONS; LLOQ; LOWER LIMIT OF QUANTITATION; NED; NMIBC; NO EVIDENCE OF DISEASE; NONMUSCLE INVASIVE BLADDER CANCER; URINARY BLADDER NEOPLASMS;

ADENOVIRIDAE; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHOLIC ACIDS; DISACCHARIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERFERON-ALPHA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECOMBINANT PROTEINS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84881475388     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.03.030     Document Type: Article

References (21)

1. R.J. Sylvester, A.P. van der Meijden, D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
2. R.J. Sylvester, A.P. van der Meijden, J.A. Witjes Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials J Urol 174 2005 86
3. D.L. Lamm, B.A. Blumenstein, J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study J Urol 163 2000 1124
4. M.S. Cookson, H.W. Herr, Z.F. Zhang The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62
5. G. Steinberg, R. Bahnson, S. Brosman Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder J Urol 163 2000 761
6. G. Dalbagni, P. Russo, J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder J Clin Oncol 20 2002 3193
7. M.A. O'Donnell, K. Lilli, C. Leopold Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer J Urol 172 2004 888
8. H.W. Herr, P.C. Sogani Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166 2001 1296
9. A.S. Belldegrun, J.R. Franklin, M.A. O'Donnell Superficial bladder cancer: the role of interferon-alpha J Urol 159 1998 1793
10. L.C. Pagliaro, A. Keyhani, D. Williams Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase 1 study of p53 gene therapy J Clin Oncol 21 2003 2247
11. R.J. Connor, H. Engler, T. Machemer Identification of polyamides that enhance adenovirous-mediated gene expression in the urothelium Gene Ther 8 2001 41
12. M. Yamashita, C.J. Rosser, J.H. Zhou Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene transfer of genetically altered urothelium and superficial bladder cancer Cancer Gene Ther 9 2002 687
13. W.F. Benedict, Z. Tao, C.S. Kim Intravesical Ad-IFN alpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein Mol Ther 10 2002 525
14. Z. Tao, R.J. Connor, F. Ashoori Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation Cancer Gene Ther 13 2006 125
15. R.J. Connor, J.M. Anderson, T. Machemer Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens Urology 66 2005 224
16. A. Papageorgiou, L. Lashinger, R. Millikan Autocrine TRAIL production mediates interferon-induced apoptosis in human bladder cancer cells Cancer Res 64 2005 8973
17. M.B. Fisher, X.Q. Zhang, D.J. McConkey Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker Cancer Gene Ther 16 2009 567
18. X.Q. Zhang, Z. Yang, L. Dong Adenoviral-mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marked bystander effects Cancer Gene Ther 14 2007 241
19. X. Zhang, L. Dong, E. Chapman Conditioned medium from Ad-IFN-alpha- infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect Cancer Gene Ther 12 2008 817
20. X.Q. Zhang, Z. Yang, W.F. Benedict Direct gene transfer of adenoviral-mediated interferon-α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity Cancer Gene Ther 18 2011 260
21. Z. Yang, X.-Q. Zhang, C.N.P. Dinney Direct cytotoxicity produced by adenoviral-mediated interferon α infection in interferon resistant cancer cells Involves ER stress and caspase 4 activation Cancer Gene Ther 18 2011 609